Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 6/2024

01.06.2024 | Research

Analysis of risk characteristics for early progression and late progression in locally advanced rectal cancer patients: a large population-based and validated study

verfasst von: Yilin Yu, Haixia Wu, Jianjian Qiu, Shiji Wu, Yixiu Gan, Lingdong Shao, Cheng Lin, Liang Hong, Junxin Wu

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

The current study aimed to explore the factors influencing early progression (EP) and late progression (LP) in locally advanced rectal cancer (LARC) patients.

Methods

The patients were classified into EP and LP groups using one year as a cutoff. The random survival forest model was utilized to calculate the probability of time-to-progression. Besides, inverse probability of treatment weighting (IPTW) analysis and the Surveillance, Epidemiology, and End Results (SEER) were conducted to validate our results.

Results

Our study revealed that PNI, CEA level, and pathological stage were independent prognostic factors for PFS both in EP group and LP group. For EP group patients, Group 1 had the highest probability of progression at the 9th month of follow-up, while Group 2 exhibited the highest probability at the 6th month. Group 3, on the other hand, showed two peaks of progression at the 4th and 8th months of follow-up. As for LP group patients, Groups 4, 5, and 6 all exhibited peaks of progression between the 18th and 24th months of follow-up. Furthermore, our results suggested that PNI was also an independent prognostic factor affecting OS in both EP group and LP group. Finally, the analysis of IPTW and SEER database further confirmed our findings.

Conclusions

Our results indicated a significant correlation between immune and nutritional status with PFS and OS in both EP and LP groups. These insights can aid healthcare professionals in effectively identifying and evaluating patients' nutritional status, enabling them to develop tailored nutrition plans and interventions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249CrossRefPubMed
2.
Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F et al (2019) Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer 144:2992–3000CrossRefPubMed
3.
Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A (2013) CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum 56:859–868CrossRefPubMed
4.
Lai CL, Lai MJ, Wu CC, Jao SW, Hsiao CW (2016) Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait.” Int J Colorectal Dis 31:413–419CrossRefPubMed
5.
Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA et al (2019) Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage ii to iii rectal cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial. Ann Surg 269:589–595CrossRefPubMed
6.
Voss RK, Lin JC, Roper MT, Al-Temimi MH, Ruan JH, Tseng WH et al (2020) Adjuvant chemotherapy does not improve recurrence-free survival in patients with stage 2 or stage 3 rectal cancer after neoadjuvant chemoradiotherapy and total mesorectal excision. Dis Colon Rectum 63:427–440CrossRefPubMed
7.
van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH et al (2014) Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol 38:448–454CrossRefPubMed
8.
Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B (2015) Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol 54:5–16CrossRefPubMed
9.
Tobert CM, Hamilton-Reeves JM, Norian LA, Hung C, Brooks NA, Holzbeierlein JM et al (2017) Emerging impact of malnutrition on surgical patients: literature review and potential implications for cystectomy in bladder cancer. J Urol 198:511–519CrossRefPubMedPubMedCentral
10.
Marshall KM, Loeliger J, Nolte L, Kelaart A, Kiss NK (2019) Prevalence of malnutrition and impact on clinical outcomes in cancer services: A comparison of two time points. Clin Nutr 38:644–651CrossRefPubMed
11.
Lu S, Liu Z, Zhou X, Wang B, Li F, Ma Y et al (2020) Preoperative fibrinogen-albumin ratio index (FARI) is a reliable prognosis and chemoradiotherapy sensitivity predictor in locally advanced rectal cancer patients undergoing radical surgery following neoadjuvant chemoradiotherapy. Cancer Manag Res 12:8555–8568CrossRefPubMedPubMedCentral
12.
Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML et al (2017) Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study. JAMA Oncol 3:e172319CrossRefPubMed
13.
Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21:1594–1598CrossRefPubMed
14.
Lee JL, Yu CS, Kim TW, Kim JH, Kim JC (2015) Rate of pulmonary metastasis varies with location of rectal cancer in the patients undergoing curative resection. World J Surg 39:759–768CrossRefPubMed
15.
Chang YT, Tsai HL, Chen YC, Li CC, Huang CW, Chen PJ et al (2023) Clinicopathological features and oncological outcomes of early and late recurrence in stage III colorectal cancer patients after adjuvant oxaliplatin-based therapy. J Oncol 2023:2439128CrossRefPubMedPubMedCentral
16.
Lu S, Liu Z, Wang B, Li F, Meng Y, Wang J et al (2021) High CFP score indicates poor prognosis and chemoradiotherapy response in LARC patients. Cancer Cell Int 21:205CrossRefPubMedPubMedCentral
17.
Hsueh SW, Liu KH, Hung CY, Kuo YC, Tsai CY, Hsu JT et al (2019) Significance of the Glasgow Prognostic Score in Predicting the Postoperative Outcome of Patients with Stage III Gastric Cancer. J Clin Med 8
18.
Filip B, Scarpa M, Cavallin F, Cagol M, Alfieri R, Saadeh L et al (2015) Postoperative outcome after oesophagectomy for cancer: nutritional status is the missing ring in the current prognostic scores. Eur J Surg Oncol 41:787–794CrossRefPubMed
19.
Watanabe M, Iwatsuki M, Iwagami S, Ishimoto T, Baba Y, Baba H (2012) Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg 36:1632–1639CrossRefPubMed
20.
Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268–274CrossRefPubMed
21.
Iseki Y, Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K et al (2015) Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer. PLoS ONE 10:e0132488CrossRefPubMedPubMedCentral
22.
23.
Levitt DG, Levitt MD (2016) Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. Int J Gen Med 9:229–255CrossRefPubMedPubMedCentral
24.
Franch-Arcas G (2001) The meaning of hypoalbuminaemia in clinical practice. Clin Nutr 20:265–269CrossRefPubMed
25.
Yang Y, Gao P, Chen X, Song Y, Shi J, Zhao J et al (2016) Prognostic significance of preoperative prognostic nutritional index in colorectal cancer: results from a retrospective cohort study and a meta-analysis. Oncotarget 7:58543–58552CrossRefPubMedPubMedCentral
26.
Sun K, Chen S, Xu J, Li G, He Y (2014) The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 140:1537–1549CrossRefPubMed
27.
Mohri Y, Inoue Y, Tanaka K, Hiro J, Uchida K, Kusunoki M (2013) Prognostic nutritional index predicts postoperative outcome in colorectal cancer. World J Surg 37:2688–2692CrossRefPubMed
28.
Jian-Hui C, Iskandar EA, Cai ShI, Chen CQ, Wu H, Xu JB et al (2016) Significance of Onodera’s prognostic nutritional index in patients with colorectal cancer: a large cohort study in a single Chinese institution. Tumour Biol 37:3277–3283CrossRefPubMed
29.
Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De’Souza A et al (2017) Colorectal cancer in India: an audit from a tertiary center in a low prevalence area. Indian J Surg Oncol 8:484–490CrossRefPubMedPubMedCentral
30.
Bausys A, Kryzauskas M, Abeciunas V, Degutyte AE, Bausys R, Strupas K et al (2022) Prehabilitation in modern colorectal cancer surgery: a comprehensive review. Cancers (Basel) 14
31.
Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S et al (2021) ESPEN practical guideline: clinical nutrition in surgery. Clin Nutr 40:4745–4761CrossRefPubMed
32.
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36:11–48CrossRefPubMed
33.
Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP et al (2017) ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 36:1187–1196CrossRefPubMed
34.
Kumpf VJ, de Aguilar-Nascimento JE, Diaz-Pizarro Graf JI, Hall AM, McKeever L, Steiger E et al (2017) ASPEN-FELANPE Clinical guidelines. JPEN J Parenter Enteral Nutr 41:104–112CrossRefPubMed
Metadaten
Titel
Analysis of risk characteristics for early progression and late progression in locally advanced rectal cancer patients: a large population-based and validated study
verfasst von
Yilin Yu
Haixia Wu
Jianjian Qiu
Shiji Wu
Yixiu Gan
Lingdong Shao
Cheng Lin
Liang Hong
Junxin Wu
Publikationsdatum
01.06.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2024
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08546-8

Weitere Artikel der Ausgabe 6/2024

Supportive Care in Cancer 6/2024 Zur Ausgabe

Research

Psychosocial and supportive care concerns of young women living with advanced breast cancer: baseline findings from a prospective virtual support intervention study

Research

“God is going to help me get through this”: spirituality perspectives from Hispanic adolescent and young adult cancer survivors

Research

Patients’ and carers’ views on research priorities in prehabilitation for cancer surgery

Research

MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients

Research

Baseline characteristics and recruitment for SWOG S1820: altering intake, managing bowel symptoms in survivors of rectal cancer (AIMS-RC)

Research

Investigating the role of TGF-β and BDNF in cancer-related depression: a primary cross-sectional study

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise